ENLV
$1.10
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.
Intraday
Recent News
Enlivex Therapeutics announces new listing of RAIN token on Kraken
Enlivex Therapeutics (ENLV) reported that its primary treasury asset, the RAIN token, has been listed on the Kraken cryptocurrency exchange effective February 9, 2026, further expanding access to the token across an additional digital asset trading platform.President's Day Sale - 70% OffUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Published first on TheFl
Nasdaq biotech firm bets $212m on new Arbitrum-based prediction market
Biopharma firm sets its sights on Rain Protocol’s native token. Rain is an Arbitrum-based prediction market protocol. Prediction markets tipped to reach $96 billion in 10 years.
Enlivex Unveils $212M Rain Token DAT Strategy as RAIN Surges Over 120%
Nasdaq-listed Enlivex Therapeutics has unveiled plans to raise about $212 million in a private placement to build a Rain token-focused digital asset treasury, positioning the project as the first prediction-markets-oriented DAT strategy by a US-listed company. The announcement coincides with a sharp move in the RAIN price on the market, ...
BC-Most Active Stocks
Nu Holdings Ltd. 36,009,954 16.06
Microcap Biotech Firm Raises $212M for Prediction Market Token Treasury Strategy
Enlivex Therapeutics is raising $212 million to invest in RAIN, the token of a blockchain-based prediction market, which will become its main treasury reserve asset.